Selective separation, detection of zotepine and mass spectral characterization of degradants by LC-MS/MS/QTOF
- PMID: 29403872
- PMCID: PMC5761085
- DOI: 10.1016/j.jpha.2013.04.002
Selective separation, detection of zotepine and mass spectral characterization of degradants by LC-MS/MS/QTOF
Abstract
A simple, precise, accurate stability-indicating gradient reversed-phase high-performance liquid chromatographic (RP-HPLC) method was developed for the quantitative determination of zotepine (ZTP) in bulk and pharmaceutical dosage forms in the presence of its degradation products (DPs). The method was developed using Phenomenex C18 column (250 mm×4.6 mm i.d., 5 µm) with a mobile phase containing a gradient mixture of solvents, A (0.05% trifluoroacetic acid (TFA), pH=3.0) and B (acetonitrile). The eluted compounds were monitored at 254 nm; the run time was within 20.0 min, in which ZTP and its DPs were well separated, with a resolution of >1.5. The stress testing of ZTP was carried out under acidic, alkaline, neutral hydrolysis, oxidative, photolytic and thermal stress conditions. ZTP was found to degrade significantly in acidic, photolytic, thermal and oxidative stress conditions and remain stable in basic and neutral conditions. The developed method was validated with respect to specificity, linearity, limit of detection, limit of quantification, accuracy, precision and robustness as per ICH guidelines. This method was also suitable for the assay determination of ZTP in pharmaceutical dosage forms. The DPs were characterized by LC-MS/MS and their fragmentation pathways were proposed.
Keywords: Bulk drugs and formulations; Characterization; ESI-Q-TOF-MS; Stability-indicating RP–HPLC method; Zotepine.
Figures
References
-
- ICH, Stability Testing of New Drug Substances and Products Q1A (R2), in: Proceedings of the International Conference on Harmonization, IFPMA, Geneva, 2003.
-
- WHO . World Health Organization; Geneva: 2007. Draft Stability Testing of Active Pharmaceutical Ingredients and Pharmaceutical Products.
-
- CPMP, Note for Guidance on Stability Testing: Stability Testing of Existing Active Substances and Related Finished Products, Committee for Proprietary Medicinal Products, EMEA, London, 2002.
-
- TPD, Guidance for Industry Stability Testing of Existing Drug Substances and Products, Therapeutic Products Directorate, Health Canada, Ottawa, ON, 2003.
-
- Singh S., Bakshi M. Guidance on conduct of stress tests to determine inherent stability of drugs. Pharm. Tech. On-line. 2000;24:1–14. http://xa.yimg.com/kq/groups/2299115/609207339/name/Guidance_Stress_Test....
LinkOut - more resources
Full Text Sources
Other Literature Sources
